Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Kari B Wisinski"'
Autor:
Hamza Bakhtiar, Marina N. Sharifi, Kyle T. Helzer, Yue Shi, Matthew L. Bootsma, Tianfu A. Shang, Matthew R. Chrostek, Tracy J. Berg, S. Carson Callahan, Viridiana Carreno, Grace C. Blitzer, Malinda T. West, Ruth M. O’Regan, Kari B. Wisinski, Martin Sjöström, Shuang G. Zhao
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract In preclinical studies, p53 loss of function impacts chemotherapy response, but this has not been consistently validated clinically. We trained a TP53-loss phenocopy gene expression signature from pan-cancer clinical samples in the TCGA. In
Externí odkaz:
https://doaj.org/article/b735ca97c9414b91b5344298927abc08
Autor:
Emily Powell, Erin Shanle, Ashley Brinkman, Jun Li, Sunduz Keles, Kari B Wisinski, Wei Huang, Wei Xu
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30993 (2012)
Estrogens play essential roles in the progression of mammary and prostatic diseases. The transcriptional effects of estrogens are transduced by two estrogen receptors, ERα and ERβ, which elicit opposing roles in regulating proliferation: ERα is pr
Externí odkaz:
https://doaj.org/article/150f00e7579b4ce1bc783a58d202f1b7
Autor:
Ticiana A. Leal, Marina N. Sharifi, Nancy Chan, Robert Wesolowski, Anita A. Turk, Justine Y. Bruce, Ruth M. O'Regan, Jens Eickhoff, Lisa M. Barroilhet, Jyoti Malhotra, Janice Mehnert, Eugenia Girda, Elizabeth Wiley, Natalie Schmitz, Shannon Andrews, Glenn Liu, Kari B. Wisinski
Publikováno v:
Cancer Medicine, Vol 11, Iss 21, Pp 3969-3981 (2022)
Abstract Background Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and pacl
Externí odkaz:
https://doaj.org/article/d110893465fc4eceb9dd0c7b44d3c53f
Autor:
Elena Shagisultanova, Kari B. Wisinski, Chelsea D. Gawryletz, Farrah M. Datko, Diana Medgyesy, Jennifer R. Diamond, Virginia F. Borges, Peter Kabos
Publikováno v:
Cancer Research. 83:OT3-09
Phosphatidylinositol 3-kinase (PI3K) pathway plays a key role in resistance to the drugs targeting human epidermal growth factor receptor 2 (HER2). Activating mutations in the gene encoding alpha catalytic subunit of PI3K (PIK3CA) are present in appr
Autor:
Hannah Krause, Marina N. Sharifi, Serena K. Wolfe, Jamie M. Sperger, Kari B. Wisinski, Ruth O’Regan, Joshua Lang
Publikováno v:
Cancer Research. 83:P1-13
Background: Triple negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, and despite recent treatment advances, clinical outcomes remain poor, particularly in the metastatic setting. TNBC is a biologically heterogeneous
Autor:
Katherine D. Crew, Garnet Anderson, Kathryn Arnold, Andrew Stieb, Jacquelyn N. Amenta, Cynthia Law, Ana Sandoval-Leon, Sarah Colonna, Tari King, Debra Mangino, Sandhya Pruthi, Maria Grosse Perdekamp, Christa Braun-Inglis, Stacy Krisher, Lisa Yee, Danielle Bertoni, Samantha Seaward, Kari B. Wisinski, Justin Floyd, Corrine Zarwan, Tarah J. Ballinger, Lindi VanderWalde, Masey M. Ross, Preston Steen, Shelly Lo, Alison Conlin, Kathleen Yost, John Ellerton, Erin Lin, Holly J. Pederson, Sagar Sardesai, Cheryl Jernigan, Dawn Hershman, Marian L. Neuhouser, Banu K. Arun, Rita Kukafka
Publikováno v:
Cancer Research. 83:OT1-15
Background: Despite evidence of substantial breast cancer risk reduction, few high-risk women adopt chemopreventive medications such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs). Women with benign breast disease, su
Autor:
Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
JCO precision oncology. 6
PURPOSE National Cancer Institute–Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family
Autor:
Kevin Kalinsky, Melissa K. Accordino, Codruta Chiuzan, Prabhjot S. Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S. Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N. Baer, Sun Y. Oh, Amelia B. Zelnak, Kari B. Wisinski, Eleni Andreopoulou, William J. Gradishar, Erica Stringer-Reasor, Sonya A. Reid, Anne O'Dea, Ruth O'Regan, Katherine D. Crew, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–)
Autor:
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen Chew, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer Burns, Rashmi Kumar
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:691-722
The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, inva
Autor:
Jose M. Ayuso, Regan Truttschel, Max M. Gong, Mouhita Humayun, Maria Virumbrales-Munoz, Ross Vitek, Mildred Felder, Stephen D. Gillies, Paul Sondel, Kari B. Wisinski, Manish Patankar, David J. Beebe, Melissa C. Skala
Publikováno v:
OncoImmunology, Vol 8, Iss 3 (2019)
Immunotherapies against solid tumors face additional challenges compared with hematological cancers. In solid tumors, immune cells and antibodies need to extravasate from vasculature, find the tumor, and migrate through a dense mass of cells. These m
Externí odkaz:
https://doaj.org/article/6a17234ddcc64c4faa63fe3776ab750c